Physician profile
Roger Hakimian
NPI 1467487397
$15,352.35
in general payments reported to CMS, 2019-2025
69 companies · $1,922 in 2025
The $1,922 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,634 · 2020: $3,243 · 2021: $274 · 2022: $904 · 2023: $2,267 · 2024: $5,108 · 2025: $1,922.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,537 · Consulting Fee: $2,600 · Education: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,537.21 |
| Consulting Fee | $2,600.00 |
| Education | $159.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,273.69 | 2019-2025 | Calquence, Lynparza, Enhertu |
| Sirtex Medical INC | $2,694.94 | 2024 | Sir-Spheres Microspheres |
| E.R. Squibb & Sons, L.L.C. | $1,200.18 | 2019-2025 | Opdivo, Opdualag, Augtyro |
| Celgene Corporation | $896.94 | 2019-2025 | Opdivo, Reblozyl, Pomalyst |
| Pfizer INC. | $740.02 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $547.76 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $454.25 | 2019-2025 | Keytruda, Lynparza, Reblozyl |
| Abbvie INC. | $369.80 | 2019-2025 | |
| Asd Specialty Healthcare, LLC | $367.96 | 2020-2025 | |
| Janssen Biotech, INC. | $292.32 | 2019-2025 | Darzalex, Erleada, Akeega |
| Takeda Pharmaceuticals U.S.A., INC. | $279.72 | 2019-2025 | Iclusig |
| Astellas Pharma US INC | $261.90 | 2019-2025 | Xtandi, Vyloy |
| Glaxosmithkline, LLC. | $252.21 | 2022-2025 | Zejula, Jemperli, Ojjaara |
| Jazz Pharmaceuticals INC. | $207.48 | 2019-2025 | |
| Acrotech Biopharma INC. | $186.11 | 2021-2025 | Beleodaq |
Show all 69 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $182.67 | 2019-2023 | Imbruvica |
| Exelixis INC. | $182.00 | 2019-2023 | Cabometyx |
| Emd Serono, INC. | $174.89 | 2022-2023 | Tepmetko, Bavencio |
| Eisai INC. | $163.86 | 2019-2025 | |
| Lilly USA, LLC | $159.04 | 2019-2025 | Retevmo, Verzenio, Jaypirca |
| Genzyme Corporation | $156.36 | 2019-2025 | |
| Genentech USA, INC. | $146.33 | 2019-2025 | Tecentriq, Perjeta, Phesgo |
| Amgen INC. | $143.09 | 2019-2023 | Xgeva, Vectibix, Nplate |
| Daiichi Sankyo INC. | $137.21 | 2022-2025 | Enhertu, Datroway |
| Array Biopharma INC | $118.54 | 2023-2024 | Mektovi, Braftovi, Xalkori |
| Genmab U.S., INC. | $110.91 | 2023-2025 | Tivdak, Epkinly |
| Geron Corporation | $106.28 | 2025 | Imetelstat, Rytelo |
| Adc Therapeutics America, INC. | $97.00 | 2024-2025 | |
| Sobi, INC | $86.85 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $78.85 | 2023-2025 | Orgovyx |
| Tempus Ai, INC | $74.27 | 2024-2025 | Xt Cdx |
| Deciphera Pharmaceuticals INC. | $73.97 | 2023-2025 | Qinlock |
| Kyowa Kirin, INC. | $70.85 | 2020-2025 | Poteligeo |
| Bayer Healthcare Pharmaceuticals INC. | $70.06 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $66.69 | 2024-2025 | Libtayo, Lynozyfic |
| Taiho Oncology, INC. | $57.83 | 2022-2025 | |
| Seagen INC. | $56.85 | 2023 | Padcev |
| Alexion Pharmaceuticals, INC. | $55.56 | 2020-2025 | Ultomiris |
| Incyte Corporation | $52.52 | 2019-2024 | Jakafi |
| Ipsen Biopharmaceuticals, INC | $50.31 | 2019-2024 | Somatuline Depot, Onivyde, Tazverik |
| G1 Therapeutics, INC. | $48.07 | 2022-2023 | Cosela |
| Mirati Therapeutics, INC. | $41.85 | 2024 | Krazati |
| Heron Therapeutics, INC. | $36.64 | 2019-2023 | Cinvanti |
| Dendreon Pharmaceuticals LLC | $34.83 | 2025 | Provenge |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.87 | 2019-2025 | |
| Recordati_rare_diseases_inc. | $31.22 | 2025 | Sylvant |
| Dova Pharmaceuticals | $30.11 | 2019-2020 | |
| Gilead Sciences, INC. | $28.01 | 2021-2023 | |
| Caris Mpi, INC. | $22.85 | 2025 | Mi Cancer Seek |
| Pharmacosmos Therapeutics INC. | $21.87 | 2025 | Monoferric |
| Rigel Pharmaceuticals, INC. | $21.29 | 2024 | Rezlidhia, Tavalisse |
| Aveo Pharmaceuticals, INC. | $20.00 | 2023 | Fotivda |
| Global Blood Therapeutics, INC. | $19.85 | 2022 | |
| Morphosys, US INC. | $19.81 | 2023 | Monjuvi |
| Legend Biotech USA INC. | $19.80 | 2025 | Carvykti |
| Apellis Pharmaceuticals, INC. | $19.06 | 2024 | Empaveli |
| Blueprint Medicines Corporation | $17.88 | 2024 | Ayvakit |
| Beone Medicines USA, INC. | $17.85 | 2025 | Brukinsa |
| Sun Pharmaceutical Industries INC. | $17.73 | 2025 | |
| Karyopharm Therapeutics INC. | $17.11 | 2024 | Xpovio |
| Janssen Pharmaceuticals, INC | $16.69 | 2019 | |
| Aadi Bioscience, INC. | $16.57 | 2024 | Fyarro |
| Kite Pharma, INC. | $16.43 | 2025 | Yescarta |
| Invivyd INC | $16.38 | 2025 | Pemgarda |
| Aurobindo Pharma USA, INC. | $15.14 | 2020 | |
| Agios Pharmaceuticals, INC. | $15.13 | 2025 | Pyrukynd |
| Verity Pharmaceuticals INC. | $14.52 | 2024 | Trelstar |
| Amag Pharmaceuticals, INC. | $12.56 | 2020 | |
| Foundation Medicine, INC. | $12.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Hakimian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.